Shares of Vivus (VVUS) are active in the post session on speculation that Johnson & Johnson...
Shares of Vivus (VVUS) are active in the post session on speculation that Johnson & Johnson (JNJ) and AstraZeneca (AZN) are considering a takeover of the drug developer due to the company's obesity drug Qsymia. Pfizer (PFE) may also take an interest should VVUS come under takeover attack, because obestity drugs are a hot item at present - with over 78M obese adults in the U.S. alone. Deal-watchers are skeptical however, noting that any deal with a chance of success would need to be in the $30-plus per share range. VVUS +1.3% AH.
From other sites
at Zacks.com (Feb 25, 2015)
at Benzinga.com (Feb 24, 2015)
at Benzinga.com (Jan 14, 2015)
at Benzinga.com (Jan 13, 2015)
at Benzinga.com (Dec 30, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs